Results 11 to 20 of about 3,132 (216)

Occlusive retinal vasculitis associated with intravitreal Faricimab injections [PDF]

open access: yesJournal of Ophthalmic Inflammation and Infection
Purpose We describe a case of occlusive vasculitis associated with intravitreal Faricimab (Vabysmo) injections. Methods A retrospective case report. Results A 52-year old man treated with monthly Faricimab injections for diabetic macula oedema presented ...
Felix F. Reichel   +5 more
doaj   +2 more sources

Intravitreal Faricimab for Previously Treated Neovascular Age-Related Macular Degeneration [PDF]

open access: yesClinical Ophthalmology
Abraham Hang, Taylor Ngo, Jaipreet Singh Virk, Kareem Moussa, Ala Moshiri, Parisa Emami-Naeini, Susanna S Park Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USACorrespondence: Susanna S Park ...
Hang A   +6 more
doaj   +4 more sources

A CASE OF HYPERTENSIVE UVEITIS WITH INTRAVITREAL FARICIMAB

open access: yesRETINAL Cases & Brief Reports, 2023
Purpose: The aim of this study was to report a novel case of hypertensive uveitis with intravitreal faricimab. Methods: This is a case report. A 69-year-old woman undergoing treatment of bilateral diabetic macular edema with intravitreal faricimab presented for routine review ...
Samantha Kitson, Andrew McAllister
openaire   +6 more sources

Early Real-World Experience of Switching to Faricimab for Macular Oedema Secondary to Vein Occlusion [PDF]

open access: yesLife
Aim: To evaluate the real-world effectiveness, durability, and safety of faricimab 6 mg in eyes with treatment-refractory retinal vein occlusion (RVO)-associated macular oedema (MO) in the United Kingdom (UK).
Muiz Musadiq   +5 more
doaj   +2 more sources

Faricimab versus Aflibercept for Discharge and Readmission in Neovascular Age-Related Macular Degeneration: A Lesion-Type Stratified, Real-World UK Analysis [PDF]

open access: yesClinical Ophthalmology
Jaskaran Singh Bhangu,1 Parinita Keshav Swarnkar,1 Christopher Stewart,2 Mohammed Rifat,1 Sarah Khalid,1 Ahmed Al-Janabi,1 Mahmoud Husseiny Awad,1 Gwyn Samuel Williams11Department of Ophthalmology, Singleton Hospital, Swansea, Wales, UK; 2Faculty of ...
Singh Bhangu J   +7 more
doaj   +2 more sources

Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations

open access: yesBMJ Open Ophthalmology
Dual inhibition of the angiopoietin (Ang)/Tie and vascular endothelial growth factor (VEGF) signalling pathways in patients with retinal diseases, such as neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DME), may induce ...
David T Wong   +4 more
semanticscholar   +3 more sources

Real‐World Treatment With Faricimab Improves Anatomical Biomarkers in Patients With Diabetic Macular Edema

open access: yesInternational Journal of Clinical Practice, Volume 2026, Issue 1, 2026.
Introduction Diabetic macular edema (DME) is a leading cause of vision loss in people with diabetes. Treatments include the use of anti–vascular endothelial growth factor (VEGF) agents such as faricimab. The aims of the study were to evaluate the effectiveness and safety of treatment with faricimab and its effect on anatomical biomarkers in a real ...
Isabel Romero-Barranca   +5 more
wiley   +2 more sources

Inflammation and Occlusive Retinal Vasculitis Post Faricimab

open access: yesJAMA Ophthalmology
ImportanceRandomized clinical trials have shown the safety and efficacy of faricimab as a novel vascular endothelial growth factor and angiopoietin-2 inhibitor in the treatment of neovascular age-related macular degeneration (nAMD) and macular edema of various etiologies.
Bruening, Will   +4 more
openaire   +3 more sources

Real-world outcomes of faricimab in treatment-naïve diabetic macular edema: The Middle East perspective. [PDF]

open access: yesSaudi J Ophthalmol
: PURPOSE: Diabetic macular edema (DME) is a major cause of visual impairment in patients with diabetic retinopathy.
AlBloushi AF   +9 more
europepmc   +2 more sources

Functional Real-World Outcomes of Aflibercept 8 mg Versus Faricimab After Loading Phase in Diabetic Macular Edema [PDF]

open access: yesOphthalmology and Therapy
Introduction Aflibercept 8 mg and faricimab provide effective anatomical and visual acuity improvements in diabetic macular edema (DME), although functional recovery may not be fully captured by conventional endpoints.
Feliciana Menna   +7 more
doaj   +2 more sources

Home - About - Disclaimer - Privacy